NEW YORK, Jan. 26, 2024 /PRNewswire/ — The Global Pompe Disease Drugs Market is to witness substantial growth, with a projected increase of USD 294.7 million at a Compound Annual Growth Rate (CAGR) of 4.16% between 2023 and 2028, as forecasted by Technavio. Pompe disease, characterized by acid alpha-glucosidase deficiency, presents challenges in diagnosis due to its rarity and diverse symptoms. Public awareness campaigns, facilitated by patient advocacy groups like the National Organization for Rare Disorders and the International Pompe Association, are playing a crucial role in empowering individuals to recognize symptoms promptly. These collective efforts to raise awareness are to drive market growth during the forecast period. For a better understanding of market dynamics and trends, download a free sample report.
Market Segmentation and Challenges:
The report explores market drivers, trends, and challenges, with a focus on factors influencing growth. Expanding newborn screening programs for Pompe disease and growing advancements in genetic diagnostics are identified as key drivers, while the small patient population poses a challenge due to the rarity of the disease.
The report segments the market based on Distribution Channel, Therapy, and Geography.
Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Therapy: Enzyme Replacement Therapy (ERT) and Substrate Reduction Therapy (SRT), and others
Regional Analysis: North America is projected to contribute 41% to the global market growth during the forecast period.
“Hospital pharmacies are set to witness significant market share growth, serving as integral components in the distribution and dispensing of medications for Pompe disease treatment.” – Technavio Explore the market contribution of different segments by downloading the free PDF sample report.
Pompe Disease Drugs Market 2024-2028 : Companies Analysis
We provide a detailed analysis of around 25 vendors operating in the Pompe Disease Drugs Market, including some of the vendors such as vendors Backed with competitive intelligence and benchmarking, our research reports on the Pompe Disease Drugs Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
The report features detailed analyses of the competitive landscape and information about market players, like Amicus Therapeutics Inc., Astellas Pharma Inc., AVROBIO Inc., Bayer AG, EpiVax Inc., F. Hoffmann La Roche Ltd., JCR Pharmaceuticals Co. Ltd., Johnson and Johnson, Maze Therapeutics Inc., Sanofi SA, and others. The qualitative and quantitative analysis helps stakeholders understand the business environment and assess the strengths and weaknesses of key market players. Buy the full report to get a detailed overview of the competitive landscape.
Market Segmentation
Pompe Disease Drugs Market is segmented as below:
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Therapy
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Others
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
Pompe Disease Drugs Market 2024-2028 : Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our pompe disease drugs market report covers the following areas:
- Pompe Disease Drugs Market size
- Pompe Disease Drugs Market trends
- Pompe Disease Drugs Market industry analysis
This study identifies Approval for new drugs for Pompe treatment as one of the prime reasons driving the pompe disease drugs market growth during the next few years.
Related Reports:
The global fabry disease drugs market size is estimated to grow by USD 859.06 million, at a CAGR of 7.43% between 2023 and 2028.
The preclinical respiration and inhalation lab equipment market size is forecast to increase by USD 4.16 million, at a CAGR of 4.29% between 2023 and 2028.
Table Of Contents :
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/global-pompe-disease-drugs-market-usd-294-7-million-growth-forecasted-at-a-cagr-of-4-16-between-2024-to-2028–technavio-302045515.html
SOURCE Technavio
